[go: up one dir, main page]

WO1992011839A1 - Anhydrous aerosol - Google Patents

Anhydrous aerosol Download PDF

Info

Publication number
WO1992011839A1
WO1992011839A1 PCT/US1991/000226 US9100226W WO9211839A1 WO 1992011839 A1 WO1992011839 A1 WO 1992011839A1 US 9100226 W US9100226 W US 9100226W WO 9211839 A1 WO9211839 A1 WO 9211839A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
propellant
foam
weight
group
Prior art date
Application number
PCT/US1991/000226
Other languages
French (fr)
Inventor
Leonard Mackles
Leonard Chavkin
Original Assignee
Leonard Mackles
Leonard Chavkin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leonard Mackles, Leonard Chavkin filed Critical Leonard Mackles
Priority to CA002099984A priority Critical patent/CA2099984A1/en
Priority to PCT/US1991/000226 priority patent/WO1992011839A1/en
Priority claimed from CA002099984A external-priority patent/CA2099984A1/en
Publication of WO1992011839A1 publication Critical patent/WO1992011839A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/24—Thermal properties
    • A61K2800/242—Exothermic; Self-heating; Heating sensation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30—Characterized by the absence of a particular group of ingredients
    • A61K2800/31—Anhydrous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q15/00—Anti-perspirants or body deodorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/02—Preparations for cleaning the hair

Definitions

  • anhydrous topically applicable aerosol f composition comprising a foamable anhydrous liquid, a foaming a selected from the group consisting of methyl glucose C 16 -C 18 aliph acid esters and a propellant, said propellant being capable of exis in gaseous form at ambient pressure and temperature and being present an amount sufficient to produce a stable measurable foam but insuffici to produce a spray when said composition is ejected through an aer valve.
  • the composition comprises from about 35 to about by weight of said foamable anhydrous liquid, from about 0.2 to about 1 by weight of said foaming agent, and from about 2 to about 15% by wei of said propellant, all % being by weight of the total composition.
  • the composition may additionally comprising between about to about 50% by weight of at least one an additional topically ac composition which may be a solid suspendable in or a material soluble the composition.
  • the active component may be a foamable liquid.
  • Non-aqueous aerosol foams have been disclosed heretofore. selection of suitable foaming agents has however been a problem. U.
  • Patent 3,135,658 to Hanus and Oulette discloses a method of trea bovine mastitis using a milk miscible, non-aqueous surfactant stabili oleaginous liquid material, which foams upon contact with the milk in cow's udder. The material which is administered does not, of it create a foam.
  • a heat generating composition one of the uses of foams disclosed herein, is disclosed in U.S. Patent 3,250,680 to Men and Ricciuti.
  • This material is not a foam but utilizes alumlnosili molecular sieve materials taken up in non-aqueous carriers such polyethylene glycol, using sorbitan monostearate or polyoxyethyl sorbitan mono oleate as surfactant materials in the composition.
  • non-aqueous aerosol foam is disclosed in U. S. Patent 3,419,658 to Sanders. The Sanders foam however is limited to white mineral oil as the anhydrous liquid. The surfactants are also rather limited to their particular category. It should be noted that the same author published a somewhat extensive review of non-aqueous aerosol foams in Soap and Chemical Specialties. November 1960, page 87 through 109.
  • the non- aqueous liquids are limited to alkylene glycols and the ethers thereof.
  • the surfactants are similarly of the propylene glycol monostearate or polyoxyethylene sorbitan monostearate type.
  • U. S. Patent 3,770,648 to Leonard Mackles is directed to an aerosol foam utilizing a silicone resin as the foaming agent.
  • U. S. Patent 4,379,143 to Sherry, et al. is directed to a topical self-heating liquid or ointment used for analgesic purposes which comprises a zeolite and an anhydrous liquid. There is no disclosure in Sherry of the possibility of foaming the compositions since no foaming agent is disclosed. Furthermore, the invention is specifically limited to the use of the zeolite as the sole warming agent.
  • U. S. Patent 4,627,973 to Moran, et al. is directed to a skin mousse. Moran, et al., however comprises a substantial amount of water and cannot therefore be considered to fall within the category of the present invention.
  • U. S. Patent 4,639,367 to Leonard Mackles is directed to an edible anhydrous aerosol foam composition comprising a foamable liquid oil, a dispersed solid foaming agent and a propellent.
  • the disclosure of this invention being directed to edible foams, does not consider the requirements necessary for foaming a topically absorbable, as opposed to an ingestible, anhydrous liquid.
  • foams be prepara from a diverse group of anhydrous liquids such as giycerol fatty a esters; e.g., soybean oil, corn oil, mono and diglycerol este acetylated monoglycerides, glyceryl triacetate; di and triethyl est of organic acids, e.g., triethyl citrate, diethyl phthalate; aroma acid esters, e.g., methyl saiicylate, benzyl benzoate; and water solu glycols, e.g., propylene glycol and polyethylene glycol 400.
  • anhydrous liquids such as giycerol fatty a esters; e.g., soybean oil, corn oil, mono and diglycerol este acetylated monoglycerides, glyceryl triacetate; di and triethyl est of organic acids, e.g., triethyl citrate, diethyl phthalate
  • giycerol fatty acid esters such as glyceryl triacetate, acetylated mo glycerides, di- and tri-ethyl esters of organic hydrocarbon acids, su as diethyl phthalate, triethyl citrate, monoesters of aromatic mo carboxylic acids such as methyl saiicylate, benzyl benzoate and wa soluble glycols such as propylene glycol or polyethylene glycol 400.
  • methyl glucose sesquiester of stearic acid a highly useful foaming agent for aerosol foam systems.
  • the ester formed by reacting methyl glucoside and stearic acid in corr proportions so as to foam the "sesqui" ester having approximately following properties:
  • methyl glucose sesquistearate a levels between 0.2-10.0% in combination with a suitable foamabl anhydrous liquid and an aerosol propellent, there can be obtained variety of foams suitable for topical application to the dermal an mucosal tissues such as cosmetics, toiletries or drugs. These foams ca be made as stiff or as soft as required by simply varying the percentag of methyl glucose sesquistearate used.
  • methyl glucose sesquistearate methyl glucose dioieate is a preferred foaming agent.
  • the preferred propellants are hydrocarbon propellants such a propane, butane, isobutane and combinations thereof, fluorocarbo propellants such as Freon 11, Freon 12, Dymel 152, Dymel 142 and the like, dimethyl ether and compressed gases such as carbon dioxide, nitrogen an nitrous oxide, 3 - 10% by weight of propellant being preferred.
  • hydrocarbon propellants such as propane, butane, isobutane and combinations thereof
  • fluorocarbo propellants such as Freon 11, Freon 12, Dymel 152, Dymel 142 and the like
  • dimethyl ether such as carbon dioxide, nitrogen an nitrous oxide, 3 - 10% by weight of propellant being preferred.
  • the composition comprise at least one such agent such as topical anesthetics or analgesics such as menthol, methyl saiicylate, benzocaine, or lidocaine, antimicrobials such as benzethonium chloride, benzaikonium chloride, antibiotics such as bacitracin, polymyxin B or streptomycin; enzymes such as streptokinase, trypsin; heat generating agents such as activated sodium aluminum silicate; skin and hair conditioners such as lanolin and stearalkonium chloride; colorants such as FD & C Red 10 Lake, FD & C Yellow #6 Lake and fragrances such as citrus and floral volatile oils.
  • topical anesthetics or analgesics such as menthol, methyl saiicylate, benzocaine, or lidocaine
  • antimicrobials such as benzethonium chloride, benzaikonium chloride, antibiotics such as bacitracin, poly
  • the resultant foam is white and dense. It is easily rubbed 5 body areas in need of analgesia.
  • the resultant foam is applied to toilet tissue and then used f anal cleansing.
  • the foam being anhydrous will not cause the toi tissue to tear.
  • the resultant foam is applied to toilet tissue and then used f anogenital area cleansing and relief of hemorrhoidal pain.
  • the foa being anhydrous, will not cause the toilet tissue to tear.
  • the resultant water soluble foam can be used on toilet tissue o by hand application to cleanse and deodorize the vaginal area.
  • Solufan 98 (Fatty ester-ether lanolin 1.00 complex)
  • Valfor G-110 anhydrous sodium 40.00 aluminosi ⁇ icat ⁇
  • This foam is applied to a previous shampooed head while the is still wet.
  • the foam will generate heat due to the exothermic react between the Valfor G-110 and water.
  • the heat promotes the penetration the oils into the hair and scalp, giving a conditioning effect to b
  • the product is rinsed off with water and the hair is then dried.
  • Bentone 38 (quaternium18-Hectorite) 1.50 Valfor G-110 (Anhydrous sodium 46.80 aluminosilicate)
  • This foam is applied to the wet face after washing with soap water. Heat is generated by the exothermic reaction between the Va G-110 and the water on the skin. The hot oils will penetrate into the pores to remove make-up, debris and dirt. The product is then rinsed o for a feeling of deep cleansing.
  • Valfor G-110 anhydrous sodium 40.00 aluminosilicate
  • the resultant foam is white and non-greasy.
  • Valfor G-110 reacts exothermically with the moisture in the skin, giving an immediate sensation of heat, which leads to better penetration of the analgesic actives and a more pronounced feeling of relief.
  • the addition of the polyethylene glycol 400 dioleate allows the moisture of the skin to more easily mix with the foam.
  • Methyl glucose dioleate 1.00 Polyethylene glycol 400 dioleate 2.00
  • Valfor G-110 (anhydrous sodium 40.00 alumlnosi ⁇ cats) Propane 3_OQ
  • the resultant foam is white and non-greasy.
  • the Valfor G-110 reacts exothermically with the moisture in t skin, giving an immediate sensation of heat, which leads to bet penetration of the analgesic actives and a more pronounced feeling relief.
  • the addition of the polyethylene glycol 400 dioleate allows t moisture of the skin to more easily mix with the foam.
  • Valfor G-110 anhydrous sodium 40.00 aluminosilicate
  • Valfor G-110 anhydrous sodium 40.00 aluminosilicate
  • the resultant foam is white and non-greasy.
  • the Valfor G-110 reacts exothermically with the moisture in the skin, giving an immediate sensation of heat, which ieads to better penetration of the analgesic actives and a more pronounced feeling of relief.
  • the addition of the polyethylene glycol 400 dioleate allows the moisture of the skin to more easily mix with the foam.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)

Abstract

There is provided an anhydrous topically applicable aerosol foam composition comprising a foamable anhydrous liquid, a foaming agent selected from the group consisting of methyl glucose C16-C18 aliphatic acid esters and a propellant, said propellant being capable of existing in gaseous form at ambient pressure and temperature and being present in an amount sufficient to produce a stable measurable foam but insufficient to produce a spray when said composition is ejected through an aerosol valve.

Description

ANHYDROUS AEROSOL
SUMMARY OF THE INVENTION
There is provided an anhydrous topically applicable aerosol f composition comprising a foamable anhydrous liquid, a foaming a selected from the group consisting of methyl glucose C16-C18 aliph acid esters and a propellant, said propellant being capable of exis in gaseous form at ambient pressure and temperature and being present an amount sufficient to produce a stable measurable foam but insuffici to produce a spray when said composition is ejected through an aer valve.
Suitably, the composition comprises from about 35 to about by weight of said foamable anhydrous liquid, from about 0.2 to about 1 by weight of said foaming agent, and from about 2 to about 15% by wei of said propellant, all % being by weight of the total composition. desired, the composition may additionally comprising between about to about 50% by weight of at least one an additional topically ac composition which may be a solid suspendable in or a material soluble the composition. The active component may be a foamable liquid.
BACKGROUND OF THE INVENTION
Non-aqueous aerosol foams have been disclosed heretofore. selection of suitable foaming agents has however been a problem. U.
Patent 3,135,658 to Hanus and Oulette, discloses a method of trea bovine mastitis using a milk miscible, non-aqueous surfactant stabili oleaginous liquid material, which foams upon contact with the milk in cow's udder. The material which is administered does not, of it create a foam. A heat generating composition, one of the uses of foams disclosed herein, is disclosed in U.S. Patent 3,250,680 to Men and Ricciuti. This material is not a foam but utilizes alumlnosili molecular sieve materials taken up in non-aqueous carriers such polyethylene glycol, using sorbitan monostearate or polyoxyethyl sorbitan mono oleate as surfactant materials in the composition. The first true non-aqueous aerosol foam is disclosed in U. S. Patent 3,419,658 to Sanders. The Sanders foam however is limited to white mineral oil as the anhydrous liquid. The surfactants are also rather limited to their particular category. It should be noted that the same author published a somewhat extensive review of non-aqueous aerosol foams in Soap and Chemical Specialties. November 1960, page 87 through 109. While Sanders projects several uses for such materials, the non- aqueous liquids are limited to alkylene glycols and the ethers thereof. Furthermore, the surfactants are similarly of the propylene glycol monostearate or polyoxyethylene sorbitan monostearate type.
U. S. Patent 3,770,648 to Leonard Mackles (one of the inventors herein) is directed to an aerosol foam utilizing a silicone resin as the foaming agent. U. S. Patent 4,379,143 to Sherry, et al., is directed to a topical self-heating liquid or ointment used for analgesic purposes which comprises a zeolite and an anhydrous liquid. There is no disclosure in Sherry of the possibility of foaming the compositions since no foaming agent is disclosed. Furthermore, the invention is specifically limited to the use of the zeolite as the sole warming agent. U. S. Patent 4,627,973 to Moran, et al., is directed to a skin mousse. Moran, et al., however comprises a substantial amount of water and cannot therefore be considered to fall within the category of the present invention.
U. S. Patent 4,639,367 to Leonard Mackles is directed to an edible anhydrous aerosol foam composition comprising a foamable liquid oil, a dispersed solid foaming agent and a propellent. However, the disclosure of this invention being directed to edible foams, does not consider the requirements necessary for foaming a topically absorbable, as opposed to an ingestible, anhydrous liquid.
U. S. Patent 4,752,465, which is a continuation-in-part of the aforementioned 4,639,367, is directed to a similar product having dispersed therein a particular proportion of solid particles. It will thus be seen that the problem of providing an anhydro topically applicable aerosol foam containing a foamable topic absorbable anhydrous liquid, has not been satisfactorily addressed the prior art. In order to provide commercially satisfactory produ in the aforementioned category, it is necessary that foams be prepara from a diverse group of anhydrous liquids such as giycerol fatty a esters; e.g., soybean oil, corn oil, mono and diglycerol este acetylated monoglycerides, glyceryl triacetate; di and triethyl est of organic acids, e.g., triethyl citrate, diethyl phthalate; aroma acid esters, e.g., methyl saiicylate, benzyl benzoate; and water solu glycols, e.g., propylene glycol and polyethylene glycol 400.
While the art, as shown by the aforementioned references, teac a large number of foaming agents, it has been our surprising finding t these foaming agents are not satisfactory for foaming all of t aforementioned anhydrous liquids.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
Among the preferred foamable liquids there may be mention giycerol fatty acid esters, such as glyceryl triacetate, acetylated mo glycerides, di- and tri-ethyl esters of organic hydrocarbon acids, su as diethyl phthalate, triethyl citrate, monoesters of aromatic mo carboxylic acids such as methyl saiicylate, benzyl benzoate and wa soluble glycols such as propylene glycol or polyethylene glycol 400.
We have found that methyl glucose sesquiester of stearic acid a highly useful foaming agent for aerosol foam systems. The ester formed by reacting methyl glucoside and stearic acid in corr proportions so as to foam the "sesqui" ester having approximately following properties:
Figure imgf000005_0001
_■
HLB: 6
Appearance: Off white solid
Utilizing this foaming agent, methyl glucose sesquistearate a levels between 0.2-10.0% in combination with a suitable foamabl anhydrous liquid and an aerosol propellent, there can be obtained variety of foams suitable for topical application to the dermal an mucosal tissues such as cosmetics, toiletries or drugs. These foams ca be made as stiff or as soft as required by simply varying the percentag of methyl glucose sesquistearate used.
In addition to the aforementioned methyl glucose sesquistearate methyl glucose dioieate is a preferred foaming agent.
The preferred propellants are hydrocarbon propellants such a propane, butane, isobutane and combinations thereof, fluorocarbo propellants such as Freon 11, Freon 12, Dymel 152, Dymel 142 and the like, dimethyl ether and compressed gases such as carbon dioxide, nitrogen an nitrous oxide, 3 - 10% by weight of propellant being preferred.
Where the foamable liquid itself is not topically active, it is desirable that the composition comprise at least one such agent such as topical anesthetics or analgesics such as menthol, methyl saiicylate, benzocaine, or lidocaine, antimicrobials such as benzethonium chloride, benzaikonium chloride, antibiotics such as bacitracin, polymyxin B or streptomycin; enzymes such as streptokinase, trypsin; heat generating agents such as activated sodium aluminum silicate; skin and hair conditioners such as lanolin and stearalkonium chloride; colorants such as FD & C Red 10 Lake, FD & C Yellow #6 Lake and fragrances such as citrus and floral volatile oils.
The foregoing components are fϊsiβd for purposes of exemplification and not limitation. The invention may be best illustrated by the following working examples.
Figure imgf000007_0001
100.00% 0 All percentages are by weight.
Procedure: Heat the triethyl citrate, methyl saiicylate a methyl glucose sesquistearate to 60°C, cool with stirring. Submit aerosol filling. Add the propellant by pressure filling.
The resultant foam is white and dense. It is easily rubbed 5 body areas in need of analgesia.
EXAMPLE 2 Anal Cleansing Foam
Glyceryl triacetate 92.00%
Methyl glucose sesquistearate 3.00 0 Propane 5.00
100.00% All percentages are by weight.
Procedure: Heat the glyceryl triacetate and methyl gluco sesquistearate to 60°C. Cool with stirring. Submit for aerosol fillin 5 Add the propellant by pressure filling.
The resultant foam is applied to toilet tissue and then used f anal cleansing. The foam being anhydrous will not cause the toi tissue to tear.
0 EXAMPLE 3 Medicated Anal Cleanser Foam
Glyceryl triacetate 88.00%
Benzocaine 5.00
Methyl glucose sesquistearate 2.00
Propane 5.00 5 100.00% All percentages are by weight. Procedure: Heat the glyceryl triacetate, benzocaine and meth glucose sesquistearate to 60°C. Cool with stirring. Submit for aeros filling. Add the propellant by pressure filling.
The resultant foam is applied to toilet tissue and then used f anogenital area cleansing and relief of hemorrhoidal pain. The foa being anhydrous, will not cause the toilet tissue to tear.
EXAMPLE 4 Vaginal Deodorant Foam Wipe
Propylene glycol 91.90% Benzethonium chloride 0.10
Methyl glucose sesquistearate 5.00
Propane 3.00
100.00% All percentages are by weight. Procedure: Heat propylene glycol, benzethonium chloride an methyl glucose sesquistearate to 60°C. Cool with stirring. Submit fo aerosol filling. Add propellant by pressure filling.
The resultant water soluble foam can be used on toilet tissue o by hand application to cleanse and deodorize the vaginal area.
EXAMPLE 5 Hot Oil Hair Conditioner Foam
Self Heating Foam Triethyl citrate 20.00%
Acetylated mono glyceride 22.20 Methyl glucose sesquistearate 3.00
Solufan 98 (Fatty ester-ether lanolin 1.00 complex)
Bentone 38 (quaternium-18- Hectorite) 1.50
Valfor G-110 (anhydrous sodium 40.00 aluminosiϊicatθ)
Isopropyl myristate 2.00
Fragrance 0.3
Propellant A-31 (isobutane) 10.00
100.00% All percentages are by weight. Procedure: Heat triethyl citrate, acetylated monoglyceri methyl glucose sesquistearate, solulan 98 and isopropyl myristate
70°C. With high speed stirring, add the Bentone 38 and Valfor G-1
Cool with stirring to 40°C, add fragrance and continue stirring u cool. Submit for aerosol filling. The propellant is pressure filled.
This foam is applied to a previous shampooed head while the is still wet. The foam will generate heat due to the exothermic react between the Valfor G-110 and water. The heat promotes the penetration the oils into the hair and scalp, giving a conditioning effect to b The product is rinsed off with water and the hair is then dried.
EXAMPLE 6 Hot Oil Facial Cleanser Foam
Self Heating Foam Acetylated Monoglycerides 22.00% Methyl glucose sesquistearate 3.00
Isopropyl myristate 15.70
Apricot kernel oil 0.10
Mink oil 0.10
Bentone 38 (quaternium18-Hectorite) 1.50 Valfor G-110 (Anhydrous sodium 46.80 aluminosilicate)
PEG 600 Dilaurate 3.50
Fragrance 0.30
Propane 7.00
100.00% All percentages are by weight.
Procedure: Heat the acetylated monoglycerides, methyl gluc sesquistearate, isopropyl myristate, apricot kernel oil, mink oil PEG 600 Dilaurate to 60°C. With high speed agitation, add the Bentone and the Valfor G-110. Cool with stirring to 40°C> add - fragrance continue stirring until cool. Submii for aerosol filling. propellant by pressure filling.
This foam is applied to the wet face after washing with soap water. Heat is generated by the exothermic reaction between the Va G-110 and the water on the skin. The hot oils will penetrate into the pores to remove make-up, debris and dirt. The product is then rinsed o for a feeling of deep cleansing.
EXAMPLE 7 Self-Heating Analgesic Foam Rub Menthol 2.00%
Diethyl phthalate 52.50
Methyl glucose sesquistearate 0.50
Polyethylene glycol 400 dioleate 2.00
Valfor G-110 (anhydrous sodium 40.00 aluminosilicate)
Propane 3.00
100.00% All percentages are by weight.
Procedure: Heat the menthol, methyl saiicylate, diethy phthalate, polyethylene glycol 400 di oieate and methyl glucose sesquistearate to 60°C. With high speed stirring, add the Valfor G-110 and cool to room temperature. Submit for aerosol filling. Add the propellant by pressure filling.
The resultant foam is white and non-greasy. When applied to the skin, the Valfor G-110 reacts exothermically with the moisture in the skin, giving an immediate sensation of heat, which leads to better penetration of the analgesic actives and a more pronounced feeling of relief. The addition of the polyethylene glycol 400 dioleate allows the moisture of the skin to more easily mix with the foam.
EXAMPLE 8 Self-Heating Analgesic Foam Rub
Menthol 2.00%
Diethyl phthalate 52.00
Methyl glucose dioleate 1.00 Polyethylene glycol 400 dioleate 2.00
Valfor G-110 (anhydrous sodium 40.00 alumlnosiϋcats) Propane 3_OQ
100.00%
All percentages are by weight. Procedure: Mix the menthol, methyl saiicylate, diet phthalate, polyethylene glycol 400 dioleate and methyl glucose diole till clear. With high speed stirring, add the Valfor G-110 until mixt is uniform. Submit for aerosol filling. Add the propellant by press filling.
The resultant foam is white and non-greasy. When applied to t skin, the Valfor G-110 reacts exothermically with the moisture in t skin, giving an immediate sensation of heat, which leads to bet penetration of the analgesic actives and a more pronounced feeling relief. The addition of the polyethylene glycol 400 dioleate allows t moisture of the skin to more easily mix with the foam.
EXAMPLE 9 Self-Heating Analgesic Foam Rub
Menthol 2.00% Methyl saiicylate 3.00
Diethyl phthalate 52.50 Methyl glucose sesquistearate 0.50
Polyethylene glycol 400 dioleate 2.00
Valfor G-110 (anhydrous sodium 40.00 aluminosilicate)
Propane 3.00
100.00%
All percentages are by weight. Procedure: Heat the menthol, methyl saiicylate, diet phthalate, polyethylene glycol 400 dioleate and methyl gluco sesquistearate to 60°C. With high speed stirring, add the Valfor G-1 and cool to room temperature. Submit for aerosol filling. Add t propellant by pressure filling. The resultant foam is white and non-greasy. When applied to t skin, the Valfor G-110 reacts exothermically with the moisture in t skin, giving an immediate sensation of heat, which leads to bet penetration of the analgesic actives and a more pronounced feeling relief. The addition of the polyethylene glycol 400 dioleate allows t moisture of the skin to more easily mix with the foam. EXAMPLE 10 Self-Healinα Analgesic Foam Rub
Menthol 2.00%
Methyl saiicylate 3.00
Diethyl phthalate 52.00 Methyl glucose dioleate 1.00
Polyethylene glycol 400 dioleate 2.00
Valfor G-110 (anhydrous sodium 40.00 aluminosilicate)
Propane 3.00 100.00%
All percentages are by weight.
Procedure: Mix the menthol, methyl saiicylate, diethyl phthalate, polyethylene glycol 400 dioleate and methyl glucose dioleate till clear. With high speed stirring, add the Valfor G-110 and mix till uniform. Submit for aerosol filling. Add the propellant by pressure filling.
The resultant foam is white and non-greasy. When applied to the skin, the Valfor G-110 reacts exothermically with the moisture in the skin, giving an immediate sensation of heat, which ieads to better penetration of the analgesic actives and a more pronounced feeling of relief. The addition of the polyethylene glycol 400 dioleate allows the moisture of the skin to more easily mix with the foam.
EXAMPLE 11 Sunscreen Foam Octyl Diethyl PABA 7.00%
Benzyl benzoate 10.00
Methyl glucose sesquistearate 3.00
Soybean Oil w/antioxidant BHA 76.70
Fragrance 0.30 Propane 3.00
100.00% All percentages are by weight.
Procedure: Heat the octyl dimethyl PABA, benzyl benzoate, methyl glucose sesquistearate and soybean oil to 60°C. Cool with stirring and submit for aerosol filling. Add propellant by pressure filling. The foam is white and easily spread on the skin. Since the fo is anhydrous and hydrophobic, it is very resistant to washing off duri swimming.

Claims

We Claim:
1. An anhydrous topically applicable aerosol foam composition comprising a) a foamable topically absorbable anhydrous liquid, b) a foaming agent selected from the group consisting of methyl glucose C16-C18 aliphatic add esters and c) a propellant, said propellant being capable of existing in gaseous form at ambient pressure and temperature and being present in an amount sufficient to produce a stable measurable foam but insufficient to produce a spray when said composition is ejected through an aerosol valve.
2. A composition of Claim 1 comprising: about 35 to about 95% by weight of the total composition of said foamable anhydrous liquid, about 0.2 to about 10% by weight of the total composition of said foaming agent . and about 2 to about 15% by weight of the total composition of said propellant.
3. A composition of Claim 2 comprising: about 3 to about 10% by weight of the total composition of said propellant.
4. A composition of Claim 1 additionally comprising between about 0.1 to about 50% by weight of the total composition of an additional topically active composition of at least one component.
5. A composition of Claim 4 wherein the active composition comprises a solid suspendable in or a material soiubie in the total composition.
6. A composition of Claim 5 comprising at least one member of the group consisting of topical anesthetics, analgesics, anti- microbials, antibiotics, enzymes, heat generating agents, skin and ha conditioners, colorants and fragrances.
7. A composition of Claim 1 wherein the foaming agent i selected from the group consisting of methyl glucose sesquistearate an methyl glucose dioleate.
8. A composition of Claim 1 wherein the propellant is selecte from the group consisting of aliphatic hydrocarbon propellant fluorocarbons, dimethyl ether propellants, carbon dioxide, nitrogen an nitrous oxide.
9. A composition of Claim 1 wherein the propellant is selecte from the group consisting of aliphatic hydrocarbon propellants.
10. A composition of Claim 1 wherein the propellant is propane.
11. A composition of Claim 1 wherein the foamable liqui comprises at least one member selected from the group consisting giycerol fatty acid esters, di-and tri-ethyl esters of organi hydrocarbon acids, monoesters of aromatic monocarboxylic acids, an water soluble glycols.
12. A composition of Claim 1 wherein the foamable liqui comprises at least one component which is a topically active substance.
PCT/US1991/000226 1991-01-08 1991-01-08 Anhydrous aerosol WO1992011839A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002099984A CA2099984A1 (en) 1991-01-08 1991-01-08 Anhydrous aerosol
PCT/US1991/000226 WO1992011839A1 (en) 1991-01-08 1991-01-08 Anhydrous aerosol

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002099984A CA2099984A1 (en) 1991-01-08 1991-01-08 Anhydrous aerosol
PCT/US1991/000226 WO1992011839A1 (en) 1991-01-08 1991-01-08 Anhydrous aerosol

Publications (1)

Publication Number Publication Date
WO1992011839A1 true WO1992011839A1 (en) 1992-07-23

Family

ID=25676356

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/000226 WO1992011839A1 (en) 1991-01-08 1991-01-08 Anhydrous aerosol

Country Status (1)

Country Link
WO (1) WO1992011839A1 (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025194A1 (en) * 1995-02-17 1996-08-22 Durand Limited Medication and apparatus and method of applying medication
WO1999017739A1 (en) * 1997-10-02 1999-04-15 Omc Holdings, Llc Aerosol ointment compositions and method of manufacture
GB2338649A (en) * 1998-06-25 1999-12-29 Brian Francis Hawtin Nasal antiseptic compositions
WO2000072805A1 (en) * 1999-05-28 2000-12-07 Unilever Plc Foamable shower oil composition
WO2009087578A3 (en) * 2008-01-08 2010-06-10 Foamix Ltd. Sensation modifying topical composition foam
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
EP2900218A4 (en) * 2012-09-27 2016-04-06 Bayer Consumer Care Holdings Llc Foaming skincare formulations
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419658A (en) * 1965-01-25 1968-12-31 Du Pont Nonaqueous aerosol foams containing mineral oil
US4110426A (en) * 1973-07-24 1978-08-29 Colgate-Palmolive Company Method of treating skin and hair with a self-heated cosmetic
US4722837A (en) * 1984-05-29 1988-02-02 Derma-Cure, Inc. Medicated shampoo composition
US4767463A (en) * 1987-04-15 1988-08-30 Union Carbide Corporation Glycosaminoglycan and cationic polymer combinations
US4892727A (en) * 1985-07-24 1990-01-09 Societe Anonyme Dite: L'oreal Cosmetic or dermopharmaceutical compositions containing a powder of sweet lupine seeds essentially free of alkaloids

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3419658A (en) * 1965-01-25 1968-12-31 Du Pont Nonaqueous aerosol foams containing mineral oil
US4110426A (en) * 1973-07-24 1978-08-29 Colgate-Palmolive Company Method of treating skin and hair with a self-heated cosmetic
US4722837A (en) * 1984-05-29 1988-02-02 Derma-Cure, Inc. Medicated shampoo composition
US4892727A (en) * 1985-07-24 1990-01-09 Societe Anonyme Dite: L'oreal Cosmetic or dermopharmaceutical compositions containing a powder of sweet lupine seeds essentially free of alkaloids
US4767463A (en) * 1987-04-15 1988-08-30 Union Carbide Corporation Glycosaminoglycan and cationic polymer combinations

Cited By (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025194A1 (en) * 1995-02-17 1996-08-22 Durand Limited Medication and apparatus and method of applying medication
WO1999017739A1 (en) * 1997-10-02 1999-04-15 Omc Holdings, Llc Aerosol ointment compositions and method of manufacture
GB2338649A (en) * 1998-06-25 1999-12-29 Brian Francis Hawtin Nasal antiseptic compositions
WO2000072805A1 (en) * 1999-05-28 2000-12-07 Unilever Plc Foamable shower oil composition
US10322085B2 (en) 2002-10-25 2019-06-18 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9539208B2 (en) 2002-10-25 2017-01-10 Foamix Pharmaceuticals Ltd. Foam prepared from nanoemulsions and uses
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US9622947B2 (en) 2002-10-25 2017-04-18 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US8840869B2 (en) 2002-10-25 2014-09-23 Foamix Ltd. Body cavity foams
US11033491B2 (en) 2002-10-25 2021-06-15 Vyne Therapeutics Inc. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10821077B2 (en) 2002-10-25 2020-11-03 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9492412B2 (en) 2002-10-25 2016-11-15 Foamix Pharmaceuticals Ltd. Penetrating pharmaceutical foam
US9320705B2 (en) 2002-10-25 2016-04-26 Foamix Pharmaceuticals Ltd. Sensation modifying topical composition foam
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US9713643B2 (en) 2002-10-25 2017-07-25 Foamix Pharmaceuticals Ltd. Foamable carriers
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9050253B2 (en) 2003-08-04 2015-06-09 Foamix Pharmaceuticals Ltd. Oleaginous pharmaceutical and cosmetic foam
US9101662B2 (en) 2003-08-04 2015-08-11 Foamix Pharmaceuticals Ltd. Compositions with modulating agents
US9636405B2 (en) 2003-08-04 2017-05-02 Foamix Pharmaceuticals Ltd. Foamable vehicle and pharmaceutical compositions thereof
US9682021B2 (en) 2006-11-14 2017-06-20 Foamix Pharmaceuticals Ltd. Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US11103454B2 (en) 2007-08-07 2021-08-31 Vyne Therapeutics Inc. Wax foamable vehicle and pharmaceutical compositions thereof
US10369102B2 (en) 2007-08-07 2019-08-06 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9662298B2 (en) 2007-08-07 2017-05-30 Foamix Pharmaceuticals Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
US8900553B2 (en) 2007-12-07 2014-12-02 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US9549898B2 (en) 2007-12-07 2017-01-24 Foamix Pharmaceuticals Ltd. Oil and liquid silicone foamable carriers and formulations
US11433025B2 (en) 2007-12-07 2022-09-06 Vyne Therapeutics Inc. Oil foamable carriers and formulations
US9795564B2 (en) 2007-12-07 2017-10-24 Foamix Pharmaceuticals Ltd. Oil-based foamable carriers and formulations
US9161916B2 (en) 2007-12-07 2015-10-20 Foamix Pharmaceuticals Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2009087578A3 (en) * 2008-01-08 2010-06-10 Foamix Ltd. Sensation modifying topical composition foam
US9884017B2 (en) 2009-04-28 2018-02-06 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10213384B2 (en) 2009-04-28 2019-02-26 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10588858B2 (en) 2009-04-28 2020-03-17 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US10363216B2 (en) 2009-04-28 2019-07-30 Foamix Pharmaceuticals Ltd. Foamable vehicles and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
US11219631B2 (en) 2009-07-29 2022-01-11 Vyne Pharmaceuticals Inc. Foamable compositions, breakable foams and their uses
US9572775B2 (en) 2009-07-29 2017-02-21 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9072667B2 (en) 2009-07-29 2015-07-07 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US10092588B2 (en) 2009-07-29 2018-10-09 Foamix Pharmaceuticals Ltd. Foamable compositions, breakable foams and their uses
US10350166B2 (en) 2009-07-29 2019-07-16 Foamix Pharmaceuticals Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
US9167813B2 (en) 2009-07-29 2015-10-27 Foamix Pharmaceuticals Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US8992896B2 (en) 2009-10-02 2015-03-31 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10967063B2 (en) 2009-10-02 2021-04-06 Vyne Therapeutics Inc. Surfactant-free, water-free formable composition and breakable foams and their uses
US10238746B2 (en) 2009-10-02 2019-03-26 Foamix Pharmaceuticals Ltd Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10265404B2 (en) 2009-10-02 2019-04-23 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US10322186B2 (en) 2009-10-02 2019-06-18 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US12138311B2 (en) 2009-10-02 2024-11-12 Journey Medical Corporation Topical tetracycline compositions
US10137200B2 (en) 2009-10-02 2018-11-27 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US8865139B1 (en) 2009-10-02 2014-10-21 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10086080B2 (en) 2009-10-02 2018-10-02 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US10463742B2 (en) 2009-10-02 2019-11-05 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10517882B2 (en) 2009-10-02 2019-12-31 Foamix Pharmaceuticals Ltd. Method for healing of an infected acne lesion without scarring
US10029013B2 (en) 2009-10-02 2018-07-24 Foamix Pharmaceuticals Ltd. Surfactant-free, water-free formable composition and breakable foams and their uses
US10610599B2 (en) 2009-10-02 2020-04-07 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10821187B2 (en) 2009-10-02 2020-11-03 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US9675700B2 (en) 2009-10-02 2017-06-13 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US10835613B2 (en) 2009-10-02 2020-11-17 Foamix Pharmaceuticals Ltd. Compositions, gels and foams with rheology modulators and uses thereof
US8871184B2 (en) 2009-10-02 2014-10-28 Foamix Ltd. Topical tetracycline compositions
US10946101B2 (en) 2009-10-02 2021-03-16 Vyne Therapeutics Inc. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US10213512B2 (en) 2009-10-02 2019-02-26 Foamix Pharmaceuticals Ltd. Topical tetracycline compositions
US8945516B2 (en) 2009-10-02 2015-02-03 Foamix Pharmaceuticals Ltd. Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
EP2900218A4 (en) * 2012-09-27 2016-04-06 Bayer Consumer Care Holdings Llc Foaming skincare formulations
US10179094B2 (en) 2012-09-27 2019-01-15 Bayer Healthcare Llc Foaming skincare formulations
US10849847B2 (en) 2016-09-08 2020-12-01 Foamix Pharamaceuticals Ltd. Compositions and methods for treating rosacea and acne
US10398641B2 (en) 2016-09-08 2019-09-03 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
US11324691B2 (en) 2016-09-08 2022-05-10 Journey Medical Corporation Compositions and methods for treating rosacea and acne

Similar Documents

Publication Publication Date Title
US5322683A (en) Anhydrous aerosol foam
WO1992011839A1 (en) Anhydrous aerosol
EP1438946B1 (en) Composition for oily foamable aerosol
JP4664750B2 (en) Self-foaming cleansing system
JP4315909B2 (en) Composition that does not require pressure and expands after application
EP1668105B1 (en) High alcohol content gel-like and foaming compositions
JP4048120B2 (en) Gelled two-phase cosmetic composition
HK1210944A1 (en) High alcohol content foaming compositions with silicone-based surfactants
JP2001515022A (en) Use of foamy skin cream, foamy skin protection cream and method for producing the same
JP5564130B1 (en) Foam type external preparation for skin
JP2006008574A5 (en)
JPS621287B2 (en)
JP2006008574A (en) Non-aqueous foam cosmetic imparting warm sensation
JP3530564B2 (en) Aerosol foam cosmetics
US20030211062A1 (en) Anhydrous skin cleaners
JPH05213734A (en) Aerosol massage agent
JP3425019B2 (en) Oily foam cleansing cosmetic
JP5180601B2 (en) Aerosol composition
US20220396724A1 (en) Cryogenic, kinetically active formulations and systems for their dispensing
JP7108502B2 (en) Effervescent composition
JPH10306276A (en) Temperature-sensitive composition, temperature-sensitive composition for aerosol and temperature-sensitive aerosol product
JP2014181241A (en) Foam-type external skin preparation
JP4338561B2 (en) Post form cosmetic
JP2004083498A (en) Foamable cosmetic
CA2099984A1 (en) Anhydrous aerosol

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2099984

Country of ref document: CA

122 Ep: pct application non-entry in european phase